The CNIO reprograms CRISPR system in mice to eliminate tumor cells without affecting healthy cells
(Centro Nacional de Investigaciones Oncol ó gicas (CNIO)) CNIO researchers destroyed Ewing's sarcoma and chronic myeloid leukaemia tumor cells by using CRISPR to cut out the fusion genes that cause them. For the first time, fusion genes have been selectively and efficiently removed using CRISPR. These genes are attracting a great deal of interest from the research community because they are unique to the tumor cell and are therefore excellent targets for the development of future drugs that only attack the tumor and are harmless for healthy cells. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 8, 2020 Category: Cancer & Oncology Source Type: news
Woman receives successful treatment for rare cancer in Charlotte
Jo Ellen Marrow was diagnosed with a rare tissue cancer called sarcoma in March 2020. She went to Levine Cancer Institute, ranked nationally by U.S. News& World Report, for treatments. Using a mixture of both virtual and in-person care due to COVID-19, she was able to receive treatment to achieve a successful recovery.
Learn more about the sarcoma and bone cancer program at Levine Cancer Institute. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - October 1, 2020 Category: Biotechnology Authors: Atrium Health Source Type: news
Pembrolizumab Shows Activity in Select Rare Sarcomas Pembrolizumab Shows Activity in Select Rare Sarcomas
The checkpoint inhibitor prolonged progression-free survival in patients with four subtypes of metastatic or unresectable locally advanced sarcomas.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 24, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Science Saturday: Regenerating muscles after cancer surgery
Advancements in microsurgery are making it possible to harness the body's healing power to regenerate muscle strength after some cancer surgeries, particularly surgery to remove soft tissue sarcoma. Mayo Clinic orthopedic oncologists are teaming with plastic surgeons in a procedure they've coined "oncoregeneration." They are seeking to perfect this procedure in which large muscle is transferred to close [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - September 18, 2020 Category: Databases & Libraries Source Type: news
Few High-Grade Soft Tissue Sarcoma Patients Receive Chemo
THURSDAY, Sept. 10, 2020 -- The rates of adults with high-grade soft tissue sarcoma (STS) who receive chemotherapy may be lower than expected, indicating a need for more aggressive systemic treatments, according to a study published in the August... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 10, 2020 Category: Pharmaceuticals Source Type: news
Insights into treating rare cancer tumours benefit patients
What is the best way to tackle sarcomas? Although clinical trials help to generate insight, they are hard to set up for rare diseases. An EU-funded project has organised several trials focusing on these malignancies, providing insight that is already helping to save more lives. It has also paved the way for further research to help patients. (Source: EUROPA - Research Information Centre)
Source: EUROPA - Research Information Centre - September 7, 2020 Category: Research Source Type: news
Chemotherapy is used to treat less than 25% of people with localized sarcoma
FINDINGSUCLA researchers have found that chemotherapy is not commonly used when treating adults with localized sarcoma, a rare type of cancer of the soft tissues or bone. In a nationwide analysis of nearly 20,000 patients whose cancer had not yet spread to other organs, the scientists learned that only 22% were treated with some form of chemotherapy.The researchers found that even among patients with the largest and most aggressive tumors, less than half (45%) received chemotherapy. The team also found that patients were more likely to be treated with chemotherapy at facilities that perform at least 55 surgeries for sarcom...
Source: UCLA Newsroom: Health Sciences - August 6, 2020 Category: Universities & Medical Training Source Type: news
Rozlytrek, Roche ’s first tumour-agnostic therapy, approved in Europe for people with NTRK fusion-positive solid tumours and for people with ROS1-positive advanced non-small cell lung cancer
Basel, 03 August 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has granted conditional marketing authorisation for Rozlytrek®(entrectinib) for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have not received a prior NTRK inhibitor, who have no satisfactory treatment options. The European Commission has also appr...
Source: Roche Media News - August 3, 2020 Category: Pharmaceuticals Source Type: news
Rozlytrek, Roche ’s first tumour-agnostic therapy, approved in Europe for people with NTRK fusion-positive solid tumours and for people with ROS1-positive advanced non-small cell lung cancer
Basel, 03 August 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has granted conditional marketing authorisation for Rozlytrek®(entrectinib) for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have not received a prior NTRK inhibitor, who have no satisfactory treatment options. The European Commission has also appr...
Source: Roche Investor Update - August 3, 2020 Category: Pharmaceuticals Source Type: news
Dana-Farber study advances understanding of rare sarcoma
In this study, scientists discover how abnormal protein disrupts gene expression in synovial sarcoma. For the first time, scientists discover the molecular basis for the cancer-specific targeting properties of the culprit fusion protein found in synovial sarcoma (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 3, 2020 Category: Cancer & Oncology Source Type: news
Stand Up To Cancer awards $1.1 million in grants to research teams
(Stand Up To Cancer) Stand Up To Cancer announced today five new awards that will cut across institutional and national lines to foster collaborative research and explore new paths to improve cancer treatment. The projects will receive a combined total of $1.1 million in funding to address some of the most pressing questions associated with colorectal, Ewing sarcoma, pancreatic, lung and pediatric cancers. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 29, 2020 Category: International Medicine & Public Health Source Type: news
A mouse model was used to determine the personalized treatment for a cancer patient
(IDIBELL-Bellvitge Biomedical Research Institute) A team from IDIBELL and ICO, using a mouse orthotopic model, conducted a real-time personalized oncology study to test the best therapeutic option to treat a type of relapse sarcoma. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 23, 2020 Category: Cancer & Oncology Source Type: news
Finding hints at novel target for Ewing sarcoma therapy
(University of Texas Health Science Center at San Antonio) A genetic code-reading machine that is overactive in the pediatric cancer Ewing sarcoma causes cell structures called nucleoli to break up, researchers found. A team at UT Health San Antonio's Greehey Children's Cancer Research Institute will study how to take advantage of this finding therapeutically. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 16, 2020 Category: International Medicine & Public Health Source Type: news
Tazemetostat Shows Promise for Pleural Mesothelioma
Five different research groups at the American Society of Clinical Oncology annual meeting last month made presentations on the effectiveness of tazemetostat, a novel protein inhibitor, in fighting various cancers.
Pleural mesothelioma was one of those cancers in which clear efficacy was demonstrated, raising hopes again for a future second-line therapy option.
“It wasn’t the breakthrough you may be looking for, but there is a set of patients now that can benefit from this treatment for a period of time,” Dr. Marianna Koczywas, medical oncologist at City of Hope cancer treatment and research center in California, tol...
Source: Asbestos and Mesothelioma News - June 24, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news
Researchers have found a molecular explanation to a longstanding enigma in viral oncology
(University of Helsinki) The oncogenic herpesvirus (HHV8 or KSHV) causes a cancer known as Kaposi's Sarcoma. An international team of scientists led by the University of Helsinki has discovered key factors that control the genome maintenance and replication of a virus responsible for lymphatic vascular cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 9, 2020 Category: Cancer & Oncology Source Type: news
